Physician profile
Frederick Lindberg
NPI 1467499582
$1,336.11
in general payments reported to CMS, 2019-2025
23 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $98.52 · 2021: $172 · 2022: $113 · 2023: $148 · 2024: $312 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $220.55 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $204.58 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $151.73 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.89 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $79.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.51 | 2019-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $71.59 | 2019-2020 | |
| Lilly USA, LLC | $63.60 | 2020-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $56.16 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $39.36 | 2020-2021 | |
| Vertiflex, INC. | $35.01 | 2019 | |
| Cranial Technologies, INC | $32.18 | 2019-2023 | Doc Band |
| Abbott Laboratories | $29.36 | 2022 | |
| Therapeuticsmd, INC. | $28.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.55 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.01 | 2023 | Eliquis |
| Ibsa Pharma INC. | $20.43 | 2020 | |
| Novo Nordisk INC | $18.93 | 2024 | |
| Amarin Pharma, INC. | $16.64 | 2021 | |
| Seqirus USA INC | $14.12 | 2025 | Flucelvax |
| Genentech USA, INC. | $12.43 | 2021 | |
| Dynavax Technologies Corporation | $5.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lindberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.